Home Tests: How reliable are rapid tests for use in home diagnostics?

At-home rapid tests (also known as home tests or self-tests) are in high demand and offer a convenient way to get an initial assessment. They expand the scope of point-of-care testing and shift parts of the testing process from the laboratory to home use. However, their results are often misinterpreted. For experts in diagnostics, laboratories, and the IVD industry, the question arises of how home tests actually perform in practical use and what technical, clinical, and regulatory challenges are associated with them.

The accuracy of home tests is determined by sensitivity and specificity, which in practice do not always match the manufacturer’s specifications:

• False-negative results occur when the concentration of the virus or antigen is below the detection limit or the sample was collected improperly.
• False-positive results can arise from nonspecific reactions or inadequate quality controls.

The prevalence of the disease is crucial for a reliable assessment: the rarer a disease is in the population, the lower the positive predictive value (PPV) of a test. In low-prevalence scenarios – such as when screening asymptomatic populations – the likelihood of false-positive results therefore increases, even with tests that have high specificity. This effect is particularly relevant in home testing.

Regulatory studies for in vitro diagnostic devices are conducted under strictly controlled conditions and by trained personnel. In everyday use, results differ due to user behavior, environmental factors, and varying prevalence. While studies typically define a representative disease rate, this rate can be significantly lower in real-world settings, which alters the PPV and NPV (negative predictive value).

Furthermore, the EU IVDR increasingly requires manufacturers to provide post-market surveillance data to demonstrate performance in practical use. This creates a shared scope of action for laboratories and manufacturers: real-world validation, data feedback, and evidence-based optimization.

The next generation of at-home tests is increasingly being supplemented by digital applications. App-based evaluations can standardize test results and reduce user errors, for example through guided step-by-step instructions or automatic interpretation of test strips. At the same time, digital interfaces enable direct transmission of results to telemedicine platforms or laboratories, allowing for closer integration of confirmatory diagnostics and counseling.

In parallel, the IVDR is tightening requirements for performance evaluation and market surveillance. For IVD manufacturers, laboratories, and point-of-care providers, this creates a growing field of innovation, ranging from user-friendly test architecture to structured feedback pathways between home tests and professional diagnostics.